Zobrazeno 1 - 10
of 64
pro vyhledávání: '"James Jiao"'
Autor:
James Jiao, Iurie Bulat, Caly Chien, Anna Mitselos, Danielle Armas, Peter Hellemans, Joan Carles, Peter Ward, Ignacio Duran
Publikováno v:
Clinical Pharmacokinetics. 59:1135-1148
Two phase I studies assessed the drug–drug interaction potential of apalutamide as a substrate and perpetrator. Study A randomized 45 healthy men to single-dose apalutamide 240 mg alone or with strong inhibitors of cytochrome P450 (CYP)3A4 (itracon
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Monika Długosz-Danecka, Carlos Panizo, Tomasz Wróbel, Raul Cordoba, Wojciech Jurczak, Juthamas Sukbuntherng, James Jiao, Anna Mitselos, Peter Hellemans, Jan de Jong, Daniele Ouellet
Publikováno v:
Pharmacology Research & Perspectives
Ibrutinib may inhibit intestinal CYP3A4 and induce CYP2B6 and/or CYP3A. Secondary to potential induction, ibrutinib may reduce the exposure and effectiveness of oral contraceptives (OCs). This phase I study evaluated the effect of ibrutinib on the ph
Autor:
Juthamas Sukbuntherng, Sofie Mesens, Jan de Jong, Daniele Ouellet, Yuhan Huang, Peter Hellemans, James Jiao
Publikováno v:
Cancer Chemotherapy and Pharmacology. 80:1227-1237
Ibrutinib is an orally administered, irreversible Bruton’s tyrosine kinase inhibitor for treatment of B-cell malignancy. This study evaluated the effects of single-dose ibrutinib at therapeutic and supratherapeutic exposures on cardiac repolarizati
Autor:
Juthamas Sukbuntherng, James Jiao, Donna Skee, Joseph Murphy, Jan de Jong, Ronald de Vries, Loeckie de Zwart, Erik Mannaert, Maarten Vliegen, Jan Snoeys, Johan W. Smit, Peter Hellemans
Publikováno v:
British Journal of Clinical Pharmacology. 81:235-245
Aims Ibrutinib, an inhibitor of Bruton's tyrosine kinase, is used in the treatment of mantle cell lymphoma or chronic lymphocytic leukaemia. Ibrutinib undergoes extensive rapid oxidative metabolism mediated by cytochrome P450 3A both at the level of
Autor:
Carlos Panizo, Jan de Jong, James Jiao, Daniel Patricia, Peter Hellemans, Raul Cordoba, Juthamas Sukbuntherng, Daniele Ouellet, Severijn De Wilde, Vijay Chauhan, Alexander Myasnikov, Loeckie de Zwart, Dzhelil Osmanov, Georgii Manikhas, Jan Snoeys, Tara Masterson
Publikováno v:
Leukemialymphoma. 59(12)
This was an open-label, multicenter, phase-1 study to evaluate the drug interaction between steady-state ibrutinib and moderate (erythromycin) and strong (voriconazole) CYP3A inhibitors in patients with B-cell malignancies and to confirm dosing recom
Autor:
Daniele Ouellet, Juthamas Sukbuntherng, Jan de Jong, James Jiao, Nahor Haddish-Berhane, Peter Hellemans
Publikováno v:
Cancer chemotherapy and pharmacology. 82(2)
This drug-interaction study evaluated the effect of omeprazole, a proton-pump inhibitor, on ibrutinib’s pharmacokinetics (PK) in healthy participants. This open-label, sequential-design study included 20 healthy adults aged 18–55 years. Ibrutinib
Autor:
Ronald de Wit, Fred Saad, Caly Chien, James Jiao, W. Jeffrey Edenfield, Margaret K. Yu, Iurie Bulat, Peter Hellemans, Bodine P.S. Belderbos, Anna Mitselos, Gerhardt Attard
Publikováno v:
Cancer Chemotherapy & Pharmacology, 82(3), 457-468. Springer-Verlag
Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology
Purpose Phase Ib study evaluating the effect of apalutamide, at therapeutic exposure, on ventricular repolarization by applying time-matched pharmacokinetics and electrocardiography (ECG) in patients with castration-resistant prostate cancer. Safety
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2fa653694a6b9a03ae51849c2c96fdf
https://pure.eur.nl/en/publications/b25a7849-8ef2-48fe-8b34-791ba2d1aaf0
https://pure.eur.nl/en/publications/b25a7849-8ef2-48fe-8b34-791ba2d1aaf0
Autor:
Jennifer L. Spratlin, James Jiao, Scott North, Caly Chien, Thomas W. Griffin, Catherine Pankras, Thian Kheoh, Christian K. Kollmannsberger, Martha Gonzalez, Kim N. Chi, Lixian Peng, Milin Acharya, Hans Stieltjes, Apexa Bernard, Nam Phuong Tran, Margaret K. Yu
Publikováno v:
The Journal of Clinical Pharmacology. 55:1406-1414
Food effect on abiraterone pharmacokinetics and safety on abiraterone acetate coadministration with low-fat or high-fat meals was examined in healthy subjects and metastatic castration-resistant prostate cancer (mCRPC) patients. Healthy subjects (n =
Autor:
Xu Steven Xu, Johan W. Smit, Carole A. Ramm, George Wang, David Madrigal, Martha Gonzalez, James Jiao, Gary D. Hammer, Elizabeth O. Buschur, Alice Y. Chang, Richard J. Auchus, Margaret K. Yu
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 99:2763-2770
Chronic supraphysiological glucocorticoid therapy controls the androgen excess of 21-hydroxylase deficiency (21OHD) but contributes to the high prevalence of obesity, glucose intolerance, and reduced bone mass in these patients. Abiraterone acetate (